Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen in multiple myeloma. Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells.
Melflufen is currently being tested in four clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study, the phase 1/2 combination study ANCHOR and the phase 2 Study BRIDGE.
The company plans for filing a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma based on data from the HORIZON study. The company targets to submit the application to the FDA in end of the first quarter of 2020.
Oncopeptides’ operates from the headquarters in Stockholm, Sweden, and from its US office in Mountain View, California. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.